Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Asenapine WHITE raspberry flavor · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Sequence 1 | EXPERIMENTAL | Subjects randomly assigned to this sequence receive in order: Treatment A, C, B, A, C, B. Each treatment was one dose, and each patient received a dose in the morning and evening for 3 consecutive days. |
| Sequence 2 | EXPERIMENTAL | Subjects randomly assigned to this sequence receive in order: Treatment A, B, C, A, B, C. Each treatment was one dose, and each patient received a dose in the morning and evening for 3 consecutive days. |
| Sequence 3 | EXPERIMENTAL | Subjects randomly assigned to this sequence receive in order: Treatment B, C, A, B, C, A. Each treatment was one dose, and each patient received a dose in the morning and evening for 3 consecutive days. |
| Sequence 4 | EXPERIMENTAL | Subjects randomly assigned to this sequence receive in order: Treatment B, A, C, B, A, C. Each treatment was one dose, and each patient received a dose in the morning and evening for 3 consecutive days. |
| Sequence 5 | EXPERIMENTAL | Subjects randomly assigned to this sequence receive in order: Treatment C, B, A, C, B, A. Each treatment was one dose, and each patient received a dose in the morning and evening for 3 consecutive days. |
| Sequence 6 | EXPERIMENTAL | Subjects randomly assigned to this sequence receive in order: Treatment C, A, B, C, A, B. Each treatment was one dose, and each patient received a dose in the morning and evening for 3 consecutive days. |
| Name | Type | Description |
|---|---|---|
| Asenapine WHITE raspberry flavor (Treatment A) | DRUG | Asenapine (Org 5222), 5 mg white raspberry flavored as fast dissolving tablets |
| Asenapine RED raspberry flavor (Treatment B) | DRUG | Asenapine (Org 5222), 5 mg red raspberry flavored as fast dissolving tablets |
| Asenapine WHITE UNFLAVORED (Treatment C) | DRUG | Asenapine (Org 5222), 5 mg WHITE UNflavored as fast dissolving tablets |
Inclusion Criteria: * are at least 18 years of age and of legal minimum age for trial participation; * are a male, or a female who is not of childbearing potential * are free from an acute exacerbation of psychosis for at least 3 months; * have a current DSM-IV diagnosis of schizophrenia (paranoid,...
Asenapine WHITE raspberry flavor is an investigational small molecule being studied for psychosis. It is a raspberry-flavored formulation of asenapine intended to improve acceptability in stable patients with a psychotic disorder. The drug is in Phase 2 clinical development and is not yet approved.
Asenapine WHITE raspberry flavor is being developed by Organon & Co. (NYSE: OGN). The company is conducting clinical research on this raspberry-flavored formulation of asenapine for the treatment of psychosis.
Asenapine WHITE raspberry flavor is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied for use in patients with psychosis.
Asenapine WHITE raspberry flavor has one completed Phase 2 clinical trial, NCT00878462, titled "An Acceptability Study of Unflavored Asenapine Versus Raspberry Flavored Asenapine in Stable Patients With a Psychotic Disorder (P07010)." The study enrolled 174 participants and was a controlled, randomized trial.
Asenapine WHITE raspberry flavor is a raspberry-flavored formulation of asenapine, a small molecule antipsychotic. The flavoring is designed to improve patient acceptability compared to the unflavored version. The drug is being studied specifically for its acceptability in patients with psychotic disorders.